FMI Foundation Medicine Inc.

FOUNDATION MEDICINE 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors of Deadline in Class Action Lawsuit Against Foundation Medicine, Inc. - (FMI)

NEW ORLEANS--(BUSINESS WIRE)--

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until September 26, 2017 to file lead plaintiff applications in a securities class action lawsuit against Foundation Medicine, Inc. (NasdaqGS: FMI). Investor losses must relate to purchases of the Company’s shares between February 26, 2014 and November 3, 2015. This action is pending in the United States District Court for the District of Massachusetts.

Get Help

Foundation Medicine investors should visit https://www.claimsfiler.com/cases/view-foundation-medicine-inc-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

EN
26/09/2017

Underlying

FMIFoundation Medicine Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Foundation Medicine Inc.

Free Trial
FMI Foundation Medi...

1 director sold

A director at Foundation Medicine Inc sold 73,173 shares at 137.000USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...

FMI FOUNDATION MEDICINE INC.
08/03/18 August 3, 2018 1 EN
 PRESS RELEASE
Free
FMI Foundation Medi...

Foundation Medicine Announces 2018 First Quarter Results and Recent Hi...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine (NASDAQ:FMI) today reported financial and operational results for the first quarter ended March 31, 2018. Highlights for the quarter included: Posted revenue of $52.8 million, 101% year-over-year growth; Reported 21,861 clinical tests, 57% year-over-year growth; Achieved broad Medicare coverage through a final National Coverage Determination (NCD) from the Centers for Medicare and Medicaid Services (CMS) for FoundationOne...

May 2, 2018 1 EN
 PRESS RELEASE
Free
FMI Foundation Medi...

Foundation Medicine Launches Gene Expression Profiling Program to Iden...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced a comprehensive gene expression profiling (GEP) program to support precision oncology clinical research and development. This initiative, which provides a natural complement to Foundation Medicine’s comprehensive genomic profiling (CGP) suite of molecular information tests, further enhances support for the Company’s biopharma partners in the efficient identification of known and novel genomic and expression-based biomarkers of response fo...

May 2, 2018 1 EN
 PRESS RELEASE
Free
FMI Foundation Medi...

Foundation Medicine, Roche and DIAN Diagnostics Collaborate to Advance...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc., (NASDAQ:FMI), F. Hoffmann-La Roche Ltd (Roche) and DIAN Diagnostics Group, Co., Ltd. (DIAN), today announced a three-party collaboration to integrate Foundation Medicine’s comprehensive genomic profiling (CGP) assays into clinical patient care in mainland China. Under the collaboration: DIAN, a leader in the development and supply of Chinese medical diagnostic products and services, becomes the exclusive clinical sequencing partner in China for...

April 26, 2018 1 EN
 PRESS RELEASE
Free
FMI Foundation Medi...

Foundation Medicine’s New Liquid Biopsy Assay Granted Breakthrough D...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Device designation (formerly Expedited Access Pathway program) for its new liquid biopsy assay, which is an expanded version of its FoundationACT® assay. The new assay will include more than 70 genes and genomic biomarkers for microsatellite instability (MSI) and blood tumor mutational burden (bTMB). If approved, this test could be the first FDA-approved liquid biopsy...

April 26, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch